-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-524843-11-00
4
Non-Small Cell Lung Cancer
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-524038-24-00
5
2026-05-22
Focal Epilepsy
-
2025-522107-18-00
4
2026-05-19
Locally advanced or metastatic Non-Small Cell Lung Cancer
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-523659-73-00
5
2026-05-11
Obesity
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-522867-13-00
4
2026-04-27
Non Small Cell Lung Cancer
-
2025-521521-33-00
10
2026-04-02
Kidney transplant rejection
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2023-508995-12-01
4
2025-12-24
Recurrent or metastatic non-small cell lung cancer (NSCLC)
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2024-512029-10-00
5
2025-12-05
Intermediate risk, non-muscle invasive bladder cancer